Stability of cefozopran hydrochloride in aqueous solutions

References

• Bryskier A. Cephems: fifty years of continuous research. J Antibiot (Tokyo) 2000;53:1028–37
   PubMed Web of Science ®Google Scholar
• Ikawa K, Nomura K, Morikawa N, et al. Pharmacokinetic–pharmacodynamic target attainment analysis of cefozopran in Japanese adult patients. J Infect Chemother 2008;14:130–6
   PubMedGoogle Scholar
• Guo W, Shen Q, Qin Y, et al. Pharmacokinetics of injected cefozopran hydrochloride in healthy volunteers. Sichuan Da Xue Xue Bao Yi Xue Ban 2012;43:711–14
   PubMedGoogle Scholar
• Zalewski P, Cielecka-Piontek J, Jelińska A. Stability of cefoselis sulfate in intravenous solutions. Asian J Chem 2013;25:7596–8
   Google Scholar
• Zalewski P, Jelińska A, Paczkowska M, et al. Stability of cefpirome sulfate in aqueous solutions. Acta Pol Pharm 2015; ( in press)
   PubMed Web of Science ®Google Scholar
• Zalewski P, Cielecka-Piontek J, Jelińska A. Stability of cefoselis sulfate in aqueous solutions. React Kinet Mech Cat 2013;108:285–92
   Web of Science ®Google Scholar
• Zalewski P, Skibiński R, Cielecka-Piontek J. Stability studies of cefpirome sulfate in the solid state: identification of degradation products. J Pharm Biomed Anal 2014;92:22–5
   PubMed Web of Science ®Google Scholar
• Zając M, Jelińska A, Zalewski P. Stability of ceftriaxone disodium in biotrakson and tartriakson. Acta Pol Pharm 2005;62:89–94
   PubMedGoogle Scholar
• Zalewski P, Cielecka-Piontek J, Garbacki P, et al. Stability-indicating HPLC method for the determination of cefcapene pivoxil. Chromatographia 2013;76:387–91
   PubMed Web of Science ®Google Scholar
• Zalewski P, Cielecka-Piontek J, Jelińska A. Development and validation of the stability-indicating LC–UV method for the determination of cefoselis sulphate. Centr Eur J Chem 2012;10:121–6
   Google Scholar
• Sudo T, Murakami Y, Uemura K, et al. Perioperative antibiotics covering bile contamination prevent abdominal infectious complications after pancreatoduodenectomy in patients with preoperative biliary drainage. World J Surg 2014;38:2952–9
   PubMed Web of Science ®Google Scholar
• Ikawa K, Mikamo H, Morikawa N, et al. Penetration into and exposure of cefozopran in pelvic retroperitoneal space exudate. J Infect Chemother 2008;14:170–1
   PubMedGoogle Scholar
• Nakane T, Tamura K, Hino M, et al. Cefozopran, meropenem, or imipenem–cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: a multicenter prospective randomized trial. J Infect Chemother 2015;21:16–22
   PubMed Web of Science ®Google Scholar
• Nomura K, Morikawa N, Ikawa K, et al. Optimized dosage and frequency of cefozopran for patients with febrile neutropenia based on population pharmacokinetic and pharmacodynamic analysis. J Antimicrob Chemother 2008;61:892–900
   PubMed Web of Science ®Google Scholar
• Sarashina T, Kobayashi R, Yoshida M, et al. A randomized trial of cefozopran versus cefepime as empirical antibiotic treatment of febrile neutropenia in pediatric cancer patients. Pediatr Blood Cancer 2014;61:1992–5
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Ito M, Sano H, et al. Clinical analysis of combination therapy for febrile neutropenic patients in childhood cancer. Pediatr Int 2013;55:65–71
   PubMed Web of Science ®Google Scholar
• Ichikawa M, Suzuki D, Ohshima J, et al. Piperacillin/tazobactam versus cefozopran for the empirical treatment of pediatric cancer patients with febrile neutropenia. Pediatr Blood Cancer 2011;57:1159–62
   PubMed Web of Science ®Google Scholar
• Sato T, Kobayashi R, Yasuda K, et al. A prospective, randomized study comparing cefozopran with piperacillin–tazobactam plus ceftazidime as empirical therapy for febrile neutropenia in children with hematological disorders. Pediatr Blood Cancer 2008;51:774–7
   PubMed Web of Science ®Google Scholar
• Sawada Y, Kabashima-Kubo R, Hino R, Nakamura M. Fatal case of toxic epidermal necrolysis caused by cefozopran and associated with psoriasis. Acta Derm Venereol 2014;94:341–2
   PubMed Web of Science ®Google Scholar
• Ikeda K, Ikawa K, Morikawa N, et al. Determination of total cefozopran concentrations in human peritoneal fluid by HPLC with cefepime as an internal standard: comparative pharmacokinetics in the fluid and plasma. J Pharm Biomed Anal 2009;49:1075–81
   PubMed Web of Science ®Google Scholar
• Ikeda K, Morikawa N, Kuribayashi M, et al. Real-time therapeutic drug monitoring of cefozopran in plasma using high-performance liquid chromatography with ultraviolet detection. J Pharm Biomed Anal 2007;45:811–16
   PubMed Web of Science ®Google Scholar
• Liu SY, Li YP, Hu CQ. Influence of impurities on the specific optical rotation of cefozopran. Pharmazie 2012;67:590–4
   PubMed Web of Science ®Google Scholar
• Liu SY, Zhang DS, Hu CQ. On the isomerisation of cefozopran in solution. Eur J Med Chem 2010;45:5808–16
   PubMed Web of Science ®Google Scholar
• ICH, Stability Testing of New Drug Substances and Products (Q1AR). International Conference on Harmonization, IFPMA. Geneva: ICH; 2000
   Google Scholar
• Djordjević Filijović N, Antonijević MD, Pavlović A, et al. The stress stability of olanzapine: studies of interactions with excipients in solid state pharmaceutical formulations. Drug Dev Ind Pharm 2015;41:502–14
   PubMed Web of Science ®Google Scholar
• Santos FL, Rolim LA, Figueirêdo CB, et al. A study of photostability and compatibility of the anti-chagas drug Benznidazole with pharmaceutics excipients. Drug Dev Ind Pharm 2015;41:63–9
   PubMed Web of Science ®Google Scholar
• Mohamed D, Elsayed I, Mohamed AF, Yehia SA. Real time stability and viability prediction of the anticancer BCG after lyophilization. Drug Dev Ind Pharm 2015;5:1–8
   Google Scholar
• Jain R, Bork O, Tucker IG. Stability of penethamate, a benzylpenicillin ester prodrug, in oily vehicles. Drug Dev Ind Pharm 2015;12:1–8
   Web of Science ®Google Scholar
• Amini-Fazl MS, Mobedi H, Barzin J. Investigation of aqueous stability of taxol in different release media. Drug Dev Ind Pharm 2014;40:519–26
   PubMed Web of Science ®Google Scholar
• Gualdesi MS, Ravetti S, Raviolo MA, Briñón MC. Preformulation studies of novel 5′-O-carbonates of lamivudine with biological activity: solubility and stability assays. Drug Dev Ind Pharm 2014;40:1246–52
   PubMed Web of Science ®Google Scholar
• Franklin SJ, Dickinson SE, Karlage KL, et al. Stability of sulforaphane for topical formulation. Drug Dev Ind Pharm 2014;40:494–502
   PubMed Web of Science ®Google Scholar
• Cielecka-Piontek J, Lewandowska K, Barszcz B, Czartek A. Solid-state stability studies of faropenem based on chromatography, spectroscopy and theoretical analysis. Drug Dev Ind Pharm 2014;40:136–43
   PubMed Web of Science ®Google Scholar
• Stanisz B, Regulska K, Kania J, Garbacki P. Effect of pharmaceutical excipients on the stability of angiotensin-converting enzyme inhibitors in their solid dosage formulations. Drug Dev Ind Pharm 2013;39:51–61
   PubMed Web of Science ®Google Scholar
• Lu Q, Ku MS. Preformulation stability study of the EGFR inhibitor HKI-272 (Neratinib) and mechanism of degradation. Drug Dev Ind Pharm 2012;38:307–13
   PubMed Web of Science ®Google Scholar
• Jain R, Wu Z, Bork O, Tucker IG. Pre-formulation and chemical stability studies of penethamate, a benzylpenicillin ester prodrug, in aqueous vehicles. Drug Dev Ind Pharm 2012;38:55–63
   PubMed Web of Science ®Google Scholar
• Mendez A, Chagastelles P, Palma E, et al. Thermal and alkaline stability of meropenem: degradation products and cytotoxicity. Int J Pharm 2008;28:95–102
   Web of Science ®Google Scholar
• Sugioka T, Asano T, Chikaraishi Y, et al. Stability and degradation pattern of cefpirome (HR 810) in aqueous solution. Chem Pharm Bull 1990;38:1998–2002
   PubMed Web of Science ®Google Scholar
• Akaho E, Nakayama H. An innovative classification of, and a new structure–activity-relationship approach to degradation kinetics of cephalosporins: an attempt to enhance the therapeutic activity. J Antibiot (Tokyo) 2003;56:379–91
   PubMed Web of Science ®Google Scholar